Skye Bioscience (SKYE) EBITDA (2012 - 2026)

Skye Bioscience (SKYE) has reported EBITDA for 15 consecutive years, with -$11.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 39.37% year-over-year to -$11.1 million in Q2 2026; TTM through Jun 2026 was -$51.9 million, a 13.71% decrease from a year earlier, with the FY2025 full-year figure at -$58.2 million, down 92.64% from the prior year.
• EBITDA was -$11.1 million for Q2 2026 at Skye Bioscience, up from -$12.7 million in the prior quarter.
• Over five years, EBITDA peaked at -$2.8 million in Q2 2023 and troughed at -$24.7 million in Q3 2023.
• A 5-year average of -$9.2 million and a median of -$8.8 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 745.43% in 2023 and surged 79.89% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$9.3 million in 2022, then surged by 55.98% to -$4.1 million in 2023, then tumbled by 161.02% to -$10.7 million in 2024, then slumped by 39.65% to -$14.9 million in 2025, then grew by 25.74% to -$11.1 million in 2026.
• The last three EBITDA figures came in at -$11.1 million (Q2 2026), -$12.7 million (Q1 2026), and -$14.9 million (Q4 2025), per Business Quant data.